Division of Clinical Research and Technological Development, Brazilian National Cancer Institute, Rio de Janeiro, Brazil.
Department of Medical Oncology, A.C Camargo Cancer Center, São Paulo, Brazil.
JCO Glob Oncol. 2022 Mar;8:e2100387. doi: 10.1200/GO.21.00387.
Sarcomas are a heterogeneous group of cancers classified as rare cancers and are often poorly characterized. In Brazil, little is known about the adult sarcoma burden and patients' clinical pathways.
We analyzed data from the Brazilian Hospital-Based Cancer Registries System, which encompasses the entire country. The histologic criteria included sarcomas according to the International Classification of Diseases for Oncology, 3rd edition. All cases were histology-based No central pathology review was performed. Patients < 18 years old were excluded. The variables were analyzed according to the center type, hospital patient volume (> 70 patients/year for 3 consecutive years), and geographical region. The results were based on valid data, and the missing values were reported.
From 2000 to 2017, a total of 312 units and 49,878 cases were identified. Missing data proportion was stable. Soft tissue sarcomas were predominant, followed by bone sarcomas and gastrointestinal stromal tumors. The Southeast concentrated on the largest number of patients (51%), of high-complexity centers (CACONs; 52%), and of patients treated at CACONs (56.9%). In all regions, the majority of patients had localized disease at diagnosis. The proportion of patients starting their treatment within 60 days from diagnosis at CACON was 59.3% and 62.3% at others. Ten hospitals achieved the established threshold for high-volume center, of which seven were CACON.
This article highlights the need for further research on the profile of patients with sarcoma in Brazil and the importance of providing them a more effective diagnostic and therapeutic approach. This initiative is critical not just for planning treatment strategies but also to allocate medical resources and to improve quality of care and sarcoma patients outcomes.
肉瘤是一组异质性癌症,被归类为罕见癌症,通常特征不明显。在巴西,人们对成人肉瘤负担和患者的临床途径知之甚少。
我们分析了巴西基于医院的癌症登记系统的数据,该系统涵盖了整个国家。组织学标准包括根据国际肿瘤学疾病分类第 3 版的肉瘤。所有病例均基于组织学,未进行中央病理审查。排除年龄<18 岁的患者。根据中心类型、医院患者数量(连续 3 年每年>70 例患者)和地理区域分析变量。结果基于有效数据,并报告了缺失值。
2000 年至 2017 年,共确定了 312 个单位和 49878 例病例。缺失数据比例保持稳定。软组织肉瘤占主导地位,其次是骨肉瘤和胃肠道间质瘤。东南部集中了最多的患者(51%)、高复杂度中心(CACON;52%)和在 CACON 接受治疗的患者(56.9%)。在所有地区,大多数患者在诊断时均为局限性疾病。在 CACON 中,60 天内开始治疗的患者比例为 59.3%,在其他医院为 62.3%。有 10 家医院达到了高容量中心的既定门槛,其中 7 家是 CACON。
本文强调了需要进一步研究巴西肉瘤患者的特征,以及为他们提供更有效诊断和治疗方法的重要性。这一举措不仅对规划治疗策略至关重要,而且对分配医疗资源、改善护理质量和肉瘤患者的预后也至关重要。